Chemical Structure (Nesina 01)
Nesina Tablet, Film Coated
Product Images NDC 64764-625
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Nesina (NDC 64764-625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Nesina 02)
This text is related to the drug Alogliptin and includes information on its renal excretion, substrate capacity for various CYP enzymes, and use in combination with other drugs. The text provides recommended doses and assessment considerations for using Alogliptin with other medications.*
Figure 2 (Nesina 03)
This seems to be a list of drugs with their dosages and recommendations for co-administration with other drugs. The first section lists drugs that are renally excreted, inhibitors or substrates of various enzymes. The second section is about Alogliptin and has a table with a ratio and 90% confidence interval. The section includes dosages for Alogliptin and recommendations for dosage adjustment when prescribed with other drugs.*
Figure 3 (Nesina 04)
This appears to be a statistical table showing the LS Mean Change in A1C (%) for Pioglitazone, Nesina, and Placebo. The table includes different doses for each treatment and a comparison between corresponding doses of Nesina alone or Pioglitazone alone. The intent-to-treat population using the last observation on the study was used for analysis. There is a significant difference between the combined treatment of Nesina and Pioglitazone compared to each treatment alone (p<0.001).*
Figure 4 (Nesina 05)
This table provides a comparison of the effectiveness of NESINA (represented by N) versus a placebo (represented by P) in relation to a certain health risk over a period of months. However, without further context, it is difficult to determine the specifics of the health risk and the significance of the findings.*
6-25bottlelabel (Nesina 06)
12-5bottlelabel (Nesina 07)
Nesina is a medication used for controlling high blood sugar levels in people with type 2 diabetes. The suggested dosage can be found in the package insert, while keeping it out of reach of children is recommended. There are 30 film-coated tablets containing 17 mg of loglptin benzocte, which is equivalent to 12.5 mg of logliptn. Takeda Pharmaceuticals America, Inc. based in Lexington, MA 02421 produces this medication. It is advised to store Nesina at a temperature of 25°C (77°F) or less, with excursions permitted between 15-30°C (59— 86°F) as per USP Controlled Room Temperature. Please note that "Do not aoospt f seal over boltte opening is broken or missing," is also printed on the label.*
25bottlelabel (Nesina 08)
This text is a medication label for Alogliptin tablets. It warns not to accept the bottle if the seal is broken or missing and to keep it out of reach of children. It also provides instructions for storage and includes details about the active ingredient and its strength. The label includes the name of the manufacturer (Takeda Pharmaceuticals) and a unique product identifier (NDC 64764-250-30). The text also mentions a Medication Guide and that this medication can only be obtained with a prescription (Rx only).*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
